| Literature DB >> 19385600 |
Cédric Charrier1, Jonathan Clarhaut, Jean-Pierre Gesson, Guillermina Estiu, Olaf Wiest, Joëlle Roche, Philippe Bertrand.
Abstract
New benzofuranones were synthesized and evaluated toward NCI-H661 non-small cell lung cancer cells. Benzamide derivatives possessed micromolar antiproliferative and histone deacetylase inhibitory activities and modulate histone H4 acetylation. Hydroxamic acids were found to be potent nanomolar antiproliferative agents and HDAC inhibitors. Computational analysis presented a rationale for the activities of the hydroxamate derivatives. Impact of the HDAC inhibition on the expression of E-cadherin and the SEMA3F tumor suppressor genes revealed new promising compounds for lung cancer treatments.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19385600 DOI: 10.1021/jm9002439
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446